--tojpeg_1476960035643_x2.jpg)
Contact
Group lead
Dr Luca Magnani
+44 (0)20 7594 2808
l.magnani@imperial.ac.uk
Related themes
Disease areas
Find out more
What we do
Gene expression is controlled via modifications of the chromatin landscape including DNA methylation, histone modifications and chromatin remodelling. Our objective is to characterize the role of the chromatin landcape in oncogenesis. A second goal is to understand how cancer cells reprogram the chromatin landscape to escape treatment.
Why it is important
We are interested in understanding the extent of interactions existing between genetic and epigenetic alterations. Cancer cells likely exploit both genetic and epigenetic mutations to promote proliferation, adaptation and invasion. Our goal is to identify the mechanisms behind drug resistance to improve cure rates for women with breast cancer.
How it can benefit patients
Our research wants to identify new biomarkers to predict which patients are more at risk of developing drug resistance and what alternative treatments might be used to reduce this risk. We are focused on later stage disease, with the idea that every patient is important, and women with metastatic disease might still be offered a longer and happier life.
Summary of current research
- Identification of the seed breast cancer cells that drive metastatic progression and drug resistance
- Targeting cholesterol biosynthesis as a new strategy to interfere with breast cancer progression
- Functional characterization of non-coding mutations driving breast cancer progression
Connections
Our researchers
Our researchers
Dr Iros G Barozzi
/prod01/channel_3/media/images/people-list/iros_2018_02--tojpeg_1540137718063_x1.jpg)
Dr Iros G Barozzi
Honorary Research Fellow
